46LOW

OCC

ORTHOCELL FPO [OCC]
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Healthcare · ASX Small Cap
$0.7600 +1.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical50
Catalyst51
Sentiment50
Fundamental83
Momentum39
Risk Gate45
Get alerts when OCC's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track OCC — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
  • Strong cash runway (15 quarters)
  • Strong revenue growth (+49%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (2% of range)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +49% — the top line is moving in the right direction
  • Beneish M-Score -1.97 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-134%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 23% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.18%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about OCC
"What's driving OCC's score?" "How does OCC compare to peers?" "Key risks for OCC?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Remplir Used in 23 Surgeries in Ukrainian soldiers
NONE Notification of cessation of securities - OCC
NONE Notification regarding unquoted securities - OCC

Recent ASX Announcements

2026-03-17 Remplir Used in 23 Surgeries in Ukrainian soldiers PRICE SENSITIVE
2026-03-16 Notification of cessation of securities - OCC
2026-03-16 Notification regarding unquoted securities - OCC
2026-03-09 Orthocell Appoints UK Distributor for Remplir PRICE SENSITIVE
2026-02-25 Appendix 3Y - Michael McNulty

Key Metrics

$202.1M
Market Cap
405K
Avg Volume
1.3x
Vol Ratio
$0.72 — $1.70
52-Week Range
0.5%
Short Interest
N/A
Cash Runway
-41.1%
ROE
-133.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 84%
LLeader vs LaggardlaggardRS: -7
IInstitutional SponsorshipweakInst: 2%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #62 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:OCC vs ATXOCC vs PNVOCC vs IMM
Scout Pro — Deeper Analysis for OCC
Try Pro free for 30 days
Share this analysis

Track OCC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required